{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:47:05Z","timestamp":1789199225675,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There are conflicting recommendations on whether to use or not to use fluoroquinolone prophylaxis in pediatric oncology patients. An international pediatric clinical practice guideline (CPG) recommends administering levofloxacin prophylaxis in patients with acute myeloblastic leukemia and relapsed acute lymphoblastic leukemia receiving intensive chemotherapy as this practice has been found to reduce episodes of fever and bacteremia. A separate European CPG does not recommend levofloxacin prophylaxis because of concerns for adverse effects, including potentiation of fluoroquinolone resistance and possible increased resistance to other classes of antibiotics. The nuance of the decision to give or not give prophylaxis is discussed in the context of published evidence defining the risks and benefits of levofloxacin prophylaxis for pediatric leukemia patients at high risk for bacterial infection. Knowledge gaps are also identified to guide further investigations to optimize the use of fluoroquinolone prophylaxis in pediatric patients receiving chemotherapy for cancer or undergoing a hematopoietic cell transplantation.<\/jats:p>","DOI":"10.1093\/jpids\/piae077","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:59:11Z","timestamp":1722034751000},"page":"486-492","source":"Crossref","is-referenced-by-count":5,"title":["Fluoroquinolone Prophylaxis in Children With Cancer: A Pro\/Con Discussion"],"prefix":"10.1093","volume":"13","author":[{"given":"Eleana","family":"Vasileiadi","sequence":"first","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-3963","authenticated-orcid":false,"given":"Kevin M","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Children\u2019s National , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-4281","authenticated-orcid":false,"given":"Brian T","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Pediatrics, Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania ,","place":["USA"]},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9093","authenticated-orcid":false,"given":"Benjamin","family":"Hanisch","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Children\u2019s National , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"2024092608353830800_CIT0001","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024092608353830800_CIT0002","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"2020 Guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024092608353830800_CIT0003","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(20)30202-0","article-title":"Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis","volume":"2","author":"Margolis","year":"2021","journal-title":"Lancet Microbe"},{"key":"2024092608353830800_CIT0004","doi-asserted-by":"crossref","first-page":"253S","DOI":"10.1592\/phco.21.16.253S.33993","article-title":"Fluoroquinolone adverse effects and drug interactions","volume":"21","author":"Fish","year":"2001","journal-title":"Pharmacotherapy"},{"key":"2024092608353830800_CIT0005","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/cncr.30791","article-title":"Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials","volume":"123","author":"Alexander","year":"2017","journal-title":"Cancer"},{"key":"2024092608353830800_CIT0006","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.leu.2403188","article-title":"Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93","volume":"18","author":"Lehrnbecher","year":"2004","journal-title":"Leukemia"},{"key":"2024092608353830800_CIT0007","doi-asserted-by":"crossref","first-page":"e26931","DOI":"10.1002\/pbc.26909","article-title":"Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Oskarsson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2024092608353830800_CIT0008","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"key":"2024092608353830800_CIT0009","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdw557","article-title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","volume":"28","author":"Inaba","year":"2017","journal-title":"Ann Oncol"},{"key":"2024092608353830800_CIT0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamapediatrics.2018.2500","article-title":"Association of Bacteremic Sepsis with long-term neurocognitive dysfunction in pediatric patients with acute lymphoblastic leukemia","volume":"172","author":"Cheung","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"2024092608353830800_CIT0011","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"2024092608353830800_CIT0012","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12885-015-1413-8","article-title":"Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009","volume":"15","author":"Mueller","year":"2015","journal-title":"BMC Cancer"},{"key":"2024092608353830800_CIT0013","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2022-165527","article-title":"Inpatient burden and clinical outcomes of febrile neutropenia in cancer patients: a National Inpatient Sample Database Analysis","volume":"140","author":"Makhani","year":"2022","journal-title":"Blood"},{"key":"2024092608353830800_CIT0014","doi-asserted-by":"crossref","first-page":"e26927","DOI":"10.1002\/pbc.26927","article-title":"Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia","volume":"65","author":"Szymczak","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2024092608353830800_CIT0015","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia [Internet]","author":"Bucaneve"},{"key":"2024092608353830800_CIT0016","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on Bacteremia in children with acute Leukemia or undergoing hematopoietic stem cell transplantation a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"J Am Med Assoc"},{"key":"2024092608353830800_CIT0017","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/cid\/cix644","article-title":"Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia","volume":"65","author":"Wolf","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024092608353830800_CIT0018","doi-asserted-by":"crossref","first-page":"e29525","DOI":"10.1002\/pbc.29525","article-title":"Levofloxacin prophylaxis for pediatric leukemia patients: longitudinal follow-up for impact on health care-associated infections","volume":"69","author":"Davis","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2024092608353830800_CIT0019","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.28524","article-title":"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis","volume":"120","author":"Yeh","year":"2014","journal-title":"Cancer"},{"key":"2024092608353830800_CIT0020","doi-asserted-by":"crossref","first-page":"21142","DOI":"10.1038\/s41598-021-00725-5","article-title":"Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia","volume":"11","author":"Yeh","year":"2021","journal-title":"Sci Rep"},{"key":"2024092608353830800_CIT0021","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/INF.0b013e3182793610","article-title":"Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy","volume":"32","author":"Laoprasopwattana","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2024092608353830800_CIT0022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/ph16030466","article-title":"Cost-effectiveness of targeted prophylaxis among allogenic stem cell transplant recipients","volume":"16","author":"Shbaklo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2024092608353830800_CIT0023","doi-asserted-by":"crossref","first-page":"ofac594","DOI":"10.1093\/ofid\/ofac594","article-title":"Effectiveness of quinolone prophylaxis in pediatric acute leukemia and hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"9","author":"Leardini","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024092608353830800_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S33906","article-title":"Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia","volume":"1","author":"Widjajanto","year":"2013","journal-title":"J Blood Med"},{"key":"2024092608353830800_CIT0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"key":"2024092608353830800_CIT0026","doi-asserted-by":"crossref","first-page":"e29053","DOI":"10.1002\/pbc.29053","article-title":"Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: a report from the Children\u2019s Oncology Group","volume":"68","author":"Thompson","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2024092608353830800_CIT0027","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1002\/cam4.3249","article-title":"Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia","volume":"9","author":"Karol","year":"2020","journal-title":"Cancer Med"},{"key":"2024092608353830800_CIT0028","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.jtct.2021.11.017","article-title":"Safety and efficacy of prophylactic Levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients","volume":"28","author":"Gardner","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024092608353830800_CIT0029","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/ph16081105","article-title":"Depressive and other adverse CNS effects of fluoroquinolones","volume":"16","author":"Wierzbi\u0144ski","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"2024092608353830800_CIT0030","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1017\/ash.2024.81","article-title":"Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences","volume":"4","author":"Davis","year":"2024","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2024092608353830800_CIT0031","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciy825","article-title":"Fluoroquinolone prophylaxis selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"68","author":"Hakki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024092608353830800_CIT0032","doi-asserted-by":"crossref","first-page":"e02494","DOI":"10.1128\/AAC.02494-19","article-title":"Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa","volume":"64","author":"Gudiol","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092608353830800_CIT0033","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/tid.12298","article-title":"Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period","volume":"16","author":"Macesic","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2024092608353830800_CIT0034","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jpids\/piad041","article-title":"Emerging resistance trends in Viridans Group Streptococci bloodstream infections among immunocompromised children receiving levofloxacin prophylaxis","volume":"12","author":"Quintero","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2024092608353830800_CIT0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jpids\/piad056","article-title":"Retrospective observational assessment of the impact of Cefepime prophylaxis in neutropenic pediatric patients with acute Myelogenous leukemia","volume":"12","author":"Almatrafi","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2024092608353830800_CIT0036","article-title":"National Center for Emerging Zoonotic and Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Antibiotic Resistance Coordination and Strategy Unit","author":"Centers for Disease Control and Prevention (U.S.)","year":"2019"},{"key":"2024092608353830800_CIT0037","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmi.2022.12.006","article-title":"Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis","volume":"29","author":"Langford","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024092608353830800_CIT0038","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/acsinfecdis.8b00158","article-title":"Fitness landscape of the immune compromised favors the emergence of antibiotic resistance","volume":"4","author":"Margolis","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2024092608353830800_CIT0039","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/ice.2019.297","article-title":"Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024092608353830800_CIT0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: Intercontinental Prospective Study of the infectious diseases working party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024092608353830800_CIT0041","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024092608353830800_CIT0042","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12879-022-07154-3","article-title":"Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients","volume":"22","author":"Torres","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2024092608353830800_CIT0043","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.bbmt.2019.04.013","article-title":"Levofloxacin versus Cefpodoxime for antibacterial prophylaxis in allogeneic stem cell transplantation","volume":"25","author":"Doan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024092608353830800_CIT0044","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.transproceed.2023.12.010","article-title":"Open-label randomized controlled study of ciprofloxacin vs rifaximin as neutropenia prophylaxis in allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Gavriilaki","year":"2024","journal-title":"Transplant Proc"},{"key":"2024092608353830800_CIT0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-023-07702-5","article-title":"FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients\u2014efficacy and microbiologic safety","volume":"24","author":"Moreno","year":"2023","journal-title":"Trials"},{"key":"2024092608353830800_CIT0046","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"2024092608353830800_CIT0047","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12879-023-08086-2","article-title":"Fluoroquinolone resistance among fecal extended spectrum \u03b2eta lactamases positive Enterobacterales isolates from children in Dar es Salaam, Tanzania","volume":"23","author":"Kibwana","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2024092608353830800_CIT0048","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00520-013-2012-3","article-title":"Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients","volume":"22","author":"Bodro","year":"2014","journal-title":"Support Care Cancer"},{"key":"2024092608353830800_CIT0049","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3343\/alm.2014.34.4.286","article-title":"Correlation between virulence genotype and fluoroquinolone resistance in Carbapenem-resistant Pseudomonas aeruginosa","volume":"34","author":"Cho","year":"2014","journal-title":"Ann Lab Med"},{"key":"2024092608353830800_CIT0050","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024092608353830800_CIT0051","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piae077\/58789824\/piae077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/9\/486\/59344527\/piae077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/9\/486\/59344527\/piae077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T08:35:57Z","timestamp":1727339757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/13\/9\/486\/7723243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piae077","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,29]]}}}